Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.70 |
| ▸ | RXRA | P19793 | 19/20 | 0.70 |
| ▸ | NR1H3 | Q13133 | 19/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589694 | 0.85 | RXRA (0.58) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL780318 | 0.83 | NR1H2 (0.86) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL30197815 | 0.82 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779338 | 0.82 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779541 | 0.82 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL15453271 | 0.82 | NR1H2 (0.57) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL3574277 | 0.82 | RXRA (0.62) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL16407940 | 0.82 | NR1H2 (0.77) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL3578848 | 0.82 | RXRA (0.63) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL3575450 | 0.81 | RXRA (0.60) | NR1H2RXRANR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3626309-B1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | UNIV ROCKEFELLER (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | NR1H2 4537/4885RXRA 2268/4885NR1H3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.